Advertisement
On July 3rd AlphaDetail launched its latest AlphaPulse(TM) survey tomeasure immediate physician awareness and reactions to the panelrecommendation. In a brief on-line survey of 52 cardiologists and 51endocrinologists AlphaDetail found:
Advertisement
To learn more about this study, please contact Bob Latshaw [email protected] or (215) 259-5601.
About AlphaDetail, Inc.:
At AlphaDetail, we have an unparalleled commitment to our clients. We area full-service primary market research firm, with a particular emphasis inlarge and complex quantitative studies for the global healthcare community.AlphaDetail is built on one of the industry's strongest foundations thatincludes a large team of exceptional analytical specialists, the industry'sleading technology platform and a flexible approach to research that helps usanswer our client's most challenging questions.-- Unaided, about 40% of physicians mentioned CV risk associated with diabetes medications as the most important development in diabetes treatment from the past month. -- When prompted, half of physicians indicated they had heard about the FDA panel recommendation to require cardiovascular safety trials for new diabetes medications -- only a day after the news was announced. -- Although most physicians from both specialties support the recommendation, twice as many cardiologists (33%) vs. endocrinologists (16%) agree strongly with it. -- However, 22% of endocrinologists disagree with the recommendation primarily because they believe it would stifle innovation and delay the availability of important new therapies. -- Physicians disagree on the most appropriate implementation of the FDA panel recommendation -- two CV safety trials vs. only one trial. -- However, more physicians believe that the two trial implementation is the most appropriate. -- Even so, a segment of physicians (25% of cardiologists and 37% of endocrinologists) would support prescribing a new diabetes therapy that is highly efficacious but has CV risk to patients that have no CV risk factors other than diabetes. -- Physicians have to make a trade-off between controlling diabetes and preventing other diabetes complications vs. preventing CV risk.
SOURCE AlphaDetail, Inc.